Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's earnings beat expectations by 0.58%. The Zacks Consensus Estimate for ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

12:42 PM ESTHealth Care Biogen offers to buy out Sage Therapeutics Biogen offers to buy out Sage Therapeutics ...

Sales are likely to have improved sequentially in the first quarter. Biogen has a collaboration with Sage Therapeutics SAGE for Zurzuvae. Biogen and Sage equally share profits and losses for the ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...